Polycystic ovary syndrome - Reply

University of Chicago, Department of Medicine, Section of Endocrinology, Chicago, USA.
New England Journal of Medicine (Impact Factor: 54.42). 04/2005; 352(12):1223-36. DOI: 10.1056/NEJMra041536
Source: PubMed
  • Source
    • "Polycystic ovary syndrome (PCOS) affects an estimated 6–18% of women of reproductive age and is a heterogeneous condition characterised by endocrine and metabolic disturbances [1] [2] [3]. Oligomenorrhoea and amenorrhoea are cardinal symptoms of PCOS and primary care management typically involves oral contraceptives and insulin-sensitising agents. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim We aim to evaluate the feasibility of, and pilot procedures for, a randomised study in the UK administering Chinese herbal medicine (CHM) to women with polycystic ovary syndrome (PCOS) related oligo- and/or amenorrhoea. Our primary aim of this feasibility study is to evaluate how appropriate oligo- and amenorrhoea is as the primary outcome of the main study. Materials and Methods A prospective, multi-centre, randomised, patient- and practitioner-blind, feasibility and pilot study will be conducted. 40 women with PCOS-related oligo- and/or amenorrhoea will be randomised to one of two parallel arms comparing standardised CHM treatment against individualised CHM treatment as usual for 6 months. Participants will be prescribed 8 g of CHM granulated extracts twice daily, totalling 16 g per day. Feasibility will be determined by collecting data on menstrual regularity, body mass index, waist hip ratio, weight, Polycystic Ovary Syndrome Questionnaire, Measure Yourself Medical Outcome Profile, Dermatology Life Quality Index, Morisky Medication Adherence Scale, modified Ferriman-Gallwey scale, liver and kidney function, practitioner-blinding questionnaire and participant feedback forms. Process data will also inform feasibility such as recruitment rate, completion rate and reasons for dropout. Statistical analysis will be piloted in this study. We will present descriptive statistics for primary and secondary variables and use analysis of variance and Chi-squared tests where appropriate. Results and Conclusion This study received ethical approval in December 2012. 40 participants were recruited between January 2013 and August 2013 and the study is expected to complete in March 2014.
    European Journal of Integrative Medicine 06/2014; 6(3). DOI:10.1016/j.eujim.2014.03.001 · 0.65 Impact Factor
  • Source
    • "Polycystic ovary syndrome (POCS) is a heterogeneous disorder characterized by chronic ovulatory dysfunction and hyperandrogenism with a reported prevalence of 5–7% in women of reproductive age [109] [110]. Despite high incidence, the etiology of PCOS remains unknown. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical benefits of statins are strongly related to their low density lipoprotein cholesterol (LDL-C) lowering properties. However, considering that the pharmacological target of statins, the 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase, is one of the upstream enzyme of the mevalonate pathway, its inhibition may determine a substantial impoverishment of additional lipid moieties required for a proper cellular function. From this hypothesis, several experimental and clinical evidence have been reported indicating additional effects of statins beyond the LDL-C lowering, in particular anti-inflammatory and immunomodulatory effects. Thus statin therapy, indicated for hyperlipidemic patients for primary and secondary prevention of coronary heart disease (CHD) have begun to be considered effective in other diseases not necessarily linked to altered lipid profile. In the present review we summarized the current clinical evidence of the efficacy and safety profile of statins in a variety of diseases, such as rheumatoid arthritis, venous thromboembolism, liver diseases, polycystic ovary syndrome, and age-related macular degeneration. As discussed in the review, pending large, well designed, randomized trials, it is reasonable to conclude that there is no definitive evidence for the use of statins in the aforementioned diseases.
    Pharmacological Research 02/2014; 88. DOI:10.1016/j.phrs.2014.02.003 · 3.98 Impact Factor
  • Source
    • "Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders, affecting approximately 5–10% of women in reproductive age. It is a complex endocrine and metabolic disorder associated with ovulatory dysfunction, hyperandrogenism, polycystic ovaries, insulin resistance, abdominal fat, and obesity [18] [19] [20] [21] [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-activated transcription factor that regulates lipid and glucose metabolism. We investigated the effects of Labisia pumila (LP) standardized water extract on PPARgamma transcriptional activity in adipocytes in vitro and in vivo. We used a rat model of dihydrotestosterone- (DHT-) induced polycystic ovary syndrome (PCOS), a condition characterized by insulin resistance. At 9 weeks of age, the PCOS rats were randomly subdivided into two groups: PCOS-LP (50 mg/kg/day of LP) and PCOS-control (1 mL of deionised water) for 4-5 weeks on the same schedule. Real-time RT-PCR was performed to determine the PPARgamma mRNA levels. LP upregulated PPARgamma mRNA level by 40% in the PCOS rats. Western blot analysis further demonstrated the increased PPARgamma protein levels in parallel with upregulation in mRNA. These observations were further proven by adipocytes culture. Differentiated 3T3-L1 adipocytes were treated with final concentration of 100 μ g/mL LP and compared to untreated control and 10 μ M of rosiglitazone (in type of thiazolidinediones). LP increased PPARgamma expressions at both mRNA and protein levels and enhanced the effect of glucose uptake in the insulin-resistant cells. The data suggest that LP may ameliorate insulin resistance in adipocytes via the upregulation of PPARgamma pathway.
    Advances in Pharmacological Sciences 07/2013; 2013:808914. DOI:10.1155/2013/808914
Show more


Available from